Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    May 2016
  1. LE TOURNEAU C, Dreno B, Kirova Y, Grob JJ, et al
    First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  2. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
    Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  3. LOSKOG A, Maleka A, Mangsbo S, Svensson E, et al
    Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  4. TATE SC, Burke TF, Hartman D, Kulanthaivel P, et al
    Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Br J Cancer. 2016;114:669-79.
    PubMed     Text format     Abstract available


    February 2016
  5. HUGDAHL E, Kalvenes MB, Puntervoll HE, Ladstein RG, et al
    BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Br J Cancer. 2016 Feb 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  6. CARTER JH, Deddens JA, Spaulding Iv NR, Lucas D, et al
    Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.
    Br J Cancer. 2016;114:444-53.
    PubMed     Text format     Abstract available


    January 2016
  7. DIEM S, Kasenda B, Spain L, Martin-Liberal J, et al
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  8. WANG A, Stefanick ML, Kapphahn K, Hedlin H, et al
    Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
    Br J Cancer. 2016 Jan 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  9. AMIROUCHENE-ANGELOZZI N, Schoumacher M, Stern MH, Cassoux N, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015;113:1746.
    PubMed     Text format    


  10. PICH C, Sarrabayrouse G, Teiti I, Mariame B, et al
    Melanoma-expressed CD70 is involved in invasion and metastasis.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  11. SIRET C, Terciolo C, Dobric A, Habib MC, et al
    Interplay between cadherins and alpha2beta1 integrin differentially regulates melanoma cell invasion.
    Br J Cancer. 2015 Oct 29. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  12. NABIL AA, Marie S, Marc-Henri S, Nathalie C, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015 Oct 27. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  13. WILKINS A, Furness A, W Corbett R, Bloomfield A, et al
    The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
    Br J Cancer. 2015 Oct 20. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    July 2015
  14. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


    June 2015
  15. TAGLIABUE E, Fargnoli MC, Gandini S, Maisonneuve P, et al
    MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  16. EL HAJJ P, Gilot D, Migault M, Theunis A, et al
    SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.
    Br J Cancer. 2015 Jun 11. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    May 2015
  17. FERRUCCI PF, Gandini S, Battaglia A, Alfieri S, et al
    Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Br J Cancer. 2015 May 26. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  18. SRIVASTAVA SK, Bhardwaj A, Arora S, Tyagi N, et al
    Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis.
    Br J Cancer. 2015 May 5. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  19. ALGAZI AP, Cha E, Ortiz-Urda SM, McCalmont T, et al
    The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    Br J Cancer. 2015;112:1326-31.
    PubMed     Text format     Abstract available


    March 2015
  20. RUTHERFORD MJ, Ironmonger L, Ormiston-Smith N, Abel GA, et al
    Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.
    Br J Cancer. 2015 Mar 3. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    February 2015
  21. BAGNARDI V, Rota M, Botteri E, Tramacere I, et al
    Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis.
    Br J Cancer. 2015;112:580-93.
    PubMed     Text format     Abstract available


    November 2014
  22. WARD ST, Li KK, Hepburn E, Weston CJ, et al
    The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
    Br J Cancer. 2014 Nov 18. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    October 2014
  23. LA ROSA F, Liso A, Bianconi F, Duca E, et al
    Seasonal variation in the month of birth in patients with skin cancer.
    Br J Cancer. 2014;111:1810-3.
    PubMed     Text format     Abstract available


  24. HEINZERLING L, Schuler G, Hartmann A, Schneider-Stock R, et al
    Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1679-80.
    PubMed     Text format    


  25. MENZIES AM, Wilmott JS, Long GV, Scolyer RA, et al
    Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
    Br J Cancer. 2014;111:1678-9.
    PubMed     Text format    


    September 2014
  26. FEDORENKO IV, Gibney GT, Sondak VK, Smalley KS, et al
    Beyond BRAF: where next for melanoma therapy?
    Br J Cancer. 2014 Sep 2. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    August 2014
  27. MIRZA KA, Tisdale MJ
    Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.
    Br J Cancer. 2014;111:903-8.
    PubMed     Text format     Abstract available


  28. WHIPPLE CA, Brinckerhoff CE
    BRAF melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.
    Br J Cancer. 2014 Aug 12. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  29. HOLDERFIELD M, Nagel TE, Stuart DD
    Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
    Br J Cancer. 2014;111:640-5.
    PubMed     Text format     Abstract available


    July 2014
  30. KALIRAI H, Dodson A, Faqir S, Damato BE, et al
    Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.
    Br J Cancer. 2014 Jul 24. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  31. GAMMONS MV, Lucas R, Dean R, Coupland SE, et al
    Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Br J Cancer. 2014 Jul 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    June 2014
  32. CARLINO MS, Haydu LE, Kakavand H, Menzies AM, et al
    Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Br J Cancer. 2014 Jun 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  33. JIN P, Civini S, Zhao Y, De Giorgi V, et al
    Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.
    Br J Cancer. 2014;110:2955-64.
    PubMed     Text format     Abstract available


    April 2014
  34. AZIMI A, Pernemalm M, Frostvik Stolt M, Hansson J, et al
    Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
    Br J Cancer. 2014 Apr 10. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  35. JIANG G, Yang CS, Xu D, Sun C, et al
    Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.
    Br J Cancer. 2014 Apr 8. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  36. WU S, Han J, Vleugels RA, Puett R, et al
    Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women.
    Br J Cancer. 2014;110:1855-61.
    PubMed     Text format     Abstract available


    March 2014
  37. CHIARION-SILENI V, Pigozzo J, Ascierto PA, Simeone E, et al
    Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
    Br J Cancer. 2014 Mar 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


    February 2014
  38. SAND M, Georgas D, Hessam S, Bechara FG, et al
    Comment on 'Strong reduction of AGO2 expression in melanoma and cellular consequences'
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format    


  39. VOLLER D, Bosserhoff A
    Reply to comment on: strong reduction of AGO2 expression in melanoma and cellular consequences.
    Br J Cancer. 2014 Feb 20. doi: 10.1038/bjc.2014.
    PubMed     Text format    


  40. POSCH C, Weihsengruber F, Bartsch K, Feichtenschlager V, et al
    Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
    Br J Cancer. 2014 Feb 11. doi: 10.1038/bjc.2014.
    PubMed     Text format     Abstract available


  41. LI X, Wu XB, Chen Q
    Statin use is not associated with reduced risk of skin cancer: a meta-analysis.
    Br J Cancer. 2014;110:802-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: